CBD Oral Solution (eCBD system Target) + Placebo
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fragile X Syndrome
Conditions
Fragile X Syndrome
Trial Timeline
May 1, 2025 → Dec 15, 2027
NCT ID
NCT06261450About CBD Oral Solution (eCBD system Target) + Placebo
CBD Oral Solution (eCBD system Target) + Placebo is a phase 2 stage product being developed by Jazz Pharmaceuticals for Fragile X Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06261450. Target conditions include Fragile X Syndrome.
Hype Score Breakdown
Clinical
12
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06261450 | Phase 2 | Recruiting |
Competing Products
14 competing products in Fragile X Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CTH120 | Connecta Therapeutics | Phase 1 | 19 |
| AFQ056 | Novartis | Phase 1 | 29 |
| AFQ056 | Novartis | Phase 2/3 | 30 |
| AFQ056 + Placebo | Novartis | Phase 2 | 35 |
| AFQ056 + Placebo | Novartis | Phase 2 | 35 |
| AFQ056 | Novartis | Phase 2 | 27 |
| AFQ056 + Placebo | Novartis | Phase 2 | 35 |
| AF056 + Placebo | Novartis | Phase 2 | 35 |
| Placebo + RO4917523 + RO4917523 | Roche | Phase 2 | 35 |
| Placebo (for RO4917523 ascending doses) + Placebo (for RO4917523 fixed dose) + RO4917523 + RO4917523 | Roche | Phase 2 | 35 |
| Placebo + RO4917523 0.5 mg + RO4917523 1.5 mg | Roche | Phase 2 | 35 |
| CBD Oral Solution + Placebo | Jazz Pharmaceuticals | Phase 2 | 39 |
| Low dose of MRM-3379 + Middle Dose of MRM-3379 + High dose of MRM-3379 + Placebo + Low dose of MRM-3379 Open-Label | Mirum Pharmaceuticals | Phase 2 | 39 |
| NNZ-2566 + Placebo | Neuren Pharmaceuticals | Phase 2 | 29 |